Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurochem Int. 2011 Feb;58(3):399-403. doi: 10.1016/j.neuint.2010.12.017. Epub 2010 Dec 24.

Silibinin: a novel inhibitor of Aβ aggregation.

Author information

  • 1Research Center of Medicinal Chemistry and Chemical Biology, Chongqing Technology and Business University, Chongqing, 400067, PR China.

Abstract

Alzheimer's disease (AD) is characterized by the abnormal aggregation of amyloid β peptide (Aβ) into extracellular fibrillar deposits known as amyloid plaque. Inhibition of Aβ aggregation is therefore viewed as a potential method to halt or slow the progression of AD. It is reported that silibinin (silybin), a flavonoid derived from the herb milk thistle (Silybum marianum), attenuates cognitive deficits induced by Aβ25-35 peptide and methamphetamine. However, it remains unclear whether silibinin interacts with Aβ peptide directly and decreases Aβ peptide-induced neurotoxicity. In the present study, we identified, through employing a ThT assay and electron microscopic imaging that silibinin also appears to act as a novel inhibitor of Aβ aggregation and this effect showed dose-dependency. We also show that silibinin prevented SH-SY5Y cells from injuries caused by Aβ(1-42)-induced oxidative stress by decreasing H(2)O(2) production in Aβ(1-42)-stressed neurons. Taken together, these results indicate that silibinin may be a novel therapeutic agent for the treatment of AD.

Crown Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

PMID:
21185897
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk